Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

BACKGROUND: Posttherapy measurable residual disease (MRD) positivity in core binding factor acute myeloid leukemia (CBF‐AML) is associated with shorter relapse‐free survival (RFS). Elimination of MRD measured via quantitative reverse transcription polymerase chain reaction (qRTPCR) for disease speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Senapati, Jayastu, Shoukier, Mahran, Garcia‐Manero, Guillermo, Wang, Xuemei, Patel, Keyur, Kadia, Tapan, Ravandi, Farhad, Pemmaraju, Naveen, Ohanian, Maro, Daver, Naval, DiNardo, Courtney, Alvarado, Yesid, Aldrich, Jeffrey, Borthakur, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303262/
https://www.ncbi.nlm.nih.gov/pubmed/35150150
http://dx.doi.org/10.1002/ajh.26496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303262/
https://www.ncbi.nlm.nih.gov/pubmed/35150150
http://dx.doi.org/10.1002/ajh.26496

Ejemplares similares